Milan Criteria for Liver Transplantation in HCC
Defines eligibility for liver transplantation in patients with hepatocellular carcinoma (HCC). Patients within Milan criteria have 4-year recurrence-free survival >85%.
Score interpretation
Patient meets Milan criteria — excellent post-transplant outcomes expected (4-year survival >85%)
→ Refer for liver transplant evaluation; bridge therapy (TACE/ablation) if waiting list time >6 months
Patient does not meet Milan criteria — standard transplant not indicated
→ Consider extended criteria (UCSF criteria); locoregional therapy; systemic treatment; palliative discussion
Interpretation bands for the Milan Criteria. Apply clinical judgement and local guidance.
References
- Mazzaferro V et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699.
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Hydroxycarbamide (Hydroxyurea) · Cytotoxic / Disease-Modifying Agent
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.